PwC provided advisory on the sale of CMO business of Kolmar Korea co., Ltd.

The PwC Korea deal team acted as lead financial advisor (sell-side) for the CMO business of Kolmar Korea co., Ltd ("Kolmar").

Kolmar Group is a leading mid-sized business in Korea that specializes in producing and selling pharmaceuticals, cosmetics and health supplements. Kolmar decided to sell the CMO business to secure financial resources and to expand into new market.

The CMO business is the 1st and 2nd largest consignment manufacturing organization (CMO) in Korea specializing in New Chemical Entities (NCEs) and generic drugs and IMM Private Equity consign domestic pharmaceuticals through all share acquisition and [both/two] business sectors to achieve market dominance in the manufacturing industry.

The deal has provided the improved financial position for Kolmar by selling its CMO business and secured funds for new expansion and enabling IMM PE its prominent presence and position in the healthcare market and an excellent track record.

This transaction valued at KRW 700 billion represented a breakthrough opportunity for PwC to establish its presence and demonstrate its competency as a "M&A Total Advisory" firm in the bio/healthcare industry where foreign investment banks dominate high value M&A activities. In addition, PwC was awarded "Best advisor for sell-side M&A" for advising this deal.

The PwC team advising on the deal was led by Gil-Ju Ryu and Sungpyo Hong.